Literature DB >> 30589490

Prediction of the varices needing treatment with non-invasive tests in patients with compensated advanced chronic liver disease.

Han Ah Lee1, Seung Up Kim2, Yeon Seok Seo1, Young-Sun Lee1, Seong Hee Kang3, Young Kul Jung1, Moon Young Kim3, Ji Hoon Kim1, Sang Gyune Kim4, Ki Tae Suk5, Soung Won Jung4, Jae Young Jang4, Hyonggin An6, Hyung Joon Yim1, Soon Ho Um1.   

Abstract

BACKGROUNDS & AIMS: The Baveno VI guidelines proposed criteria including liver stiffness (LS) and platelet count to avoid screening endoscopy in patients with compensated advanced chronic liver disease (cACLD). This study was performed to validate the Baveno IV criteria and to compare its diagnostic accuracy with other non-invasive models.
METHODS: Patients with cACLD who underwent laboratory tests, upper gastrointestinal endoscopy and abdominal ultrasound within 6 months of transient elastography were included.
RESULTS: A total of 1218 patients with cACLD were included. VNT occurred in 249 patients (20.4%). With the Baveno VI criteria, the VNT miss rate was 1.9% with a 25.7% saved endoscopy rate. Using two criteria of LS <20 kPa and platelet count >110 × 109  cells/L or LS <25 kPa and platelet count >120 × 109  cells/L, the saved endoscopy rate was 39.1% while maintaining the VNT miss rate <5%. The optimal LS and platelet count-based criteria for predicting VNT differed according to the underlying liver disease. The area under the receiver operating characteristic curve of LS-spleen diameter to platelet score (LSPS) was 0.780 (95% confidence interval: 0.774-0.820), which was significantly higher than other models. The optimal cut-off value of the LSPS for predicting VNT was 1.47.
CONCLUSION: Liver stiffness and platelet count-based criteria are useful for discriminating patients with very low risk of having VNT among patients with cACLD and are partly affected by the type of underlying liver disease. Conversely, the LSPS is a predictor of VNT in patients with cACLD regardless of the type of underlying liver disease.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  platelet; prophylaxis; spleen; transient elastography; varices

Year:  2019        PMID: 30589490     DOI: 10.1111/liv.14036

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  10 in total

1.  Validation of the Expanded Baveno-VI Criteria for Screening Gastroscopy in Asian Patients with Compensated Advanced Chronic Liver Disease.

Authors:  Pik-Eu Chang; Chee-Kiat Tan; Chang-Chuen Cheah; Weiquan Li; Wan Cheng Chow; Yu-Jun Wong
Journal:  Dig Dis Sci       Date:  2020-05-21       Impact factor: 3.199

2.  Unlocking the benefits of the Baveno VI guidance when screening for varices: an audit of clinical practice across London.

Authors:  Michael Colwill; Luke Lake; Ahmed El-Sayed; Jonathan King; Rawen Kader; Eathar Shakweh; Andra Caracostea; Louise China; James Maurice
Journal:  Future Healthc J       Date:  2022-03

3.  Association of the Modified ALBI Grade With Endoscopic Findings of Gastroesophageal Varices.

Authors:  Yuho Miyamoto; Hirayuki Enomoto; Hiroki Nishikawa; Takashi Nishimura; Yoshinori Iwata; Shuhei Nishiguchi; Hiroko Iijima
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

4.  Baveno Criteria Safely Identify Patients With Compensated Advanced Chronic Liver Disease Who Can Avoid Variceal Screening Endoscopy: A Diagnostic Test Accuracy Meta-Analysis.

Authors:  Zsolt Szakács; Bálint Erőss; Alexandra Soós; Péter Mátrai; Imre Szabó; Erika Pétervári; Judit Bajor; Nelli Farkas; Péter Hegyi; Anita Illés; Margit Solymár; Márta Balaskó; Patrícia Sarlós; Ákos Szűcs; József Czimmer; Áron Vincze; Gabriella Pár
Journal:  Front Physiol       Date:  2019-08-13       Impact factor: 4.566

5.  KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2020-01-10

6.  Validation and comparison of non-invasive prediction models based on liver stiffness measurement to identify patients who could avoid gastroscopy.

Authors:  Youwen Hu; Zhili Wen
Journal:  Sci Rep       Date:  2021-01-08       Impact factor: 4.379

7.  Validation of PH and Varices Risk Scores for Prediction of High-Risk Esophageal Varix and Bleeding in Patients with B-Viral Cirrhosis.

Authors:  Seunghwan Shin; Seung Up Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Beom Kyung Kim
Journal:  Diagnostics (Basel)       Date:  2022-02-09

8.  Validation of the Combined Model Based on Platelet Count and Albumin to Rule out High-Risk Varices in Liver Cirrhosis.

Authors:  Zhihui Duan; Li Li; Jinlong Li; Shengyun Zhou
Journal:  Biomed Res Int       Date:  2020-07-13       Impact factor: 3.411

9.  Identification of potential metabolic biomarkers in predicting esophageal varices needing treatment in patients with liver cirrhosis.

Authors:  Chung-Man Moon; Yun-Young Lee; Suk-Hee Heo; Sang-Soo Shin; Yong-Yeon Jeong
Journal:  Sci Rep       Date:  2021-10-04       Impact factor: 4.379

10.  Development and Validation of an Easy-to-Use Risk Scoring System for Screening High-Risk Varices in Patients with HBV-Related Compensated Advanced Chronic Liver Disease.

Authors:  Yuling Yan; Xian Xing; Xiaoze Wang; Ruoting Men; Xuefeng Luo; Li Yang
Journal:  Dig Dis Sci       Date:  2021-01-12       Impact factor: 3.199

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.